Diabetes Linked to Higher Parkinson's Risk ( Studies Also Show Eating Soy Nuts May R...)

Diabetes Linked to Higher Parkinson's Risk

Studies Also Show Eating Soy Nuts May Reduce Inflammation After Menopause; Weight-Loss Surgery Improves Beta Cell Function, Reduces Insulin Resistance

ALEXANDRIA, Va., March 28, 2007 /PRNewswire/ -- People who have type 2 diabetes are more likely to develop Parkinson's disease as they age, though researchers are uncertain what accounts for the link between the two diseases, according to a new study being published in the April issue of Diabetes Care.

The study, by researchers in Finland, is the first large prospective study to find type 2 diabetes to be a risk factor for Parkinson's disease, a movement disorder characterized by muscle rigidity and tremors.

According to the authors, people with type 2 diabetes are 83 percent more likely to be diagnosed with Parkinson's than people in the general population. The study found the association between the two diseases existed for both men and women, independently of other confounding factors.

"Diabetes might increase the risk of Parkinson's disease partly through excess body weight," the researchers hypothesized, since their work showed that excess body weight was also associated with an elevated risk of Parkinson's disease. However, they concluded that more research needed to be done to fully understand the mechanisms behind this link.

Soy Nut Consumption Reduces Markers of Inflammation

Eating soy nuts instead of red meat decreases some markers of inflammation and improves endothelial function in postmenopausal women with a collection of cardiometabolic risk factors, a new study by researchers at Isfahan University of Medical Sciences in Iran and the Harvard School of Public Health found. In previous studies by the same group, subjects who ate soy nuts also showed improvements in their lipid profiles, suggesting that soy may improve cardiac health among a subgroup of women.

Previous research has looked at the effect of soy o
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
2. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
3. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
4. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
5. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
8. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
9. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
10. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
11. Phase IIIb Clinical Data Validate the Overall and Cardiovascular Safety Profile of Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) in Patients with Type 2 Diabetes

Post Your Comments:

( Studies Also Show Eating Soy Nuts May R...)Diabetes Linked to Higher Parkinson's Risk,Health